GC
AZN icon

Garde Capital’s AstraZeneca AZN Stock Holding History

Garde Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-459
Closed -$64.1K – 299
2025
Q2 		$64.1K Hold
459
– – ﹤0.01% 325
2025
Q1 		$67.4K Buy
+459
New +$66.4K ﹤0.01% 311
2022
Q1 		– Sell
-1,441
Closed -$168K – 275
2021
Q4 		$168K Buy
1,441
+400
+38% +$47.1K 0.02% 233
2021
Q3 		$125K Buy
1,041
+8
+0.8% +$931 0.01% 246
2021
Q2 		$124K Hold
1,033
– – 0.01% 245
2021
Q1 		$103K Buy
1,033
+4
+0.4% +$402 0.01% 253
2020
Q4 		$102K Buy
+1,029
New +$109K 0.01% 245

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Garde Capital's AZN Position: Q3 2025 in Review

Garde Capital sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 459 shares — an estimated $64.1K sold.

Garde Capital first reported a position in AZN in Q4 2020 and held it in 7 quarters. The position peaked at $168K in Q4 2021. 1,289 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

  • Garde Capital reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
  • Garde Capital sold 459 AstraZeneca shares in Q3 2025, an estimated $64.1K.
  • Garde Capital first reported a position in AstraZeneca in Q4 2020 and held it in 7 quarters.
  • Garde Capital's AstraZeneca position peaked at $168K in Q4 2021.
  • 1,289 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.